pharma · Dry Eye · Conjunctivitis, Allergic · ALDX
Aldeyra Therapeutics
Aldeyra Therapeutics clinical programs — 8 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 131 Hartwell Avenue, Suite 320, Lexington, Massachusetts 02421, US
- Founded
- 2004
- Employees
- 14
- Programs
- 26
- Drugs
- 12
- Patents
- 38
Aldeyra Therapeutics projects
8 ClinicalTrials.gov programs sponsored by Aldeyra Therapeutics.
Aldeyra Therapeutics has 8 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
ADX-102 1% Topical Dermal Cream (reproxalap)
Aldeyra Therapeutics
Sjogren-Larsson Syndrome
1 trial -
ADX-102 Ophthalmic Solution (0.5%)
Aldeyra Therapeutics
Non-infectious Anterior Uveitis
1 trial -
ADX-2191 (intravitreal methotrexate 0.8%)
Aldeyra Therapeutics
Proliferative Vitreoretinopathy
1 trial -
ICM ADX-2191 injection
Aldeyra Therapeutics
Primary Vitreoretinal Lymphoma
1 trial -
Reproxalap Ophthalmic Solution (0.25%)
Aldeyra Therapeutics
Allergic Conjunctivitis
4 trials -
Reproxalap Ophthalmic Solution (0.25%)
Aldeyra Therapeutics
Dry Eye
4 trials -
Reproxalap Ophthalmic Solution (0.25%)
Aldeyra Therapeutics
Dry Eye Disease
4 trials -
Reproxalap Ophthalmic Solution (0.25%) QID
Aldeyra Therapeutics
Dry Eye
1 trial
Frequently asked questions
How many clinical projects does Aldeyra Therapeutics have?
8 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.